文献速递炎症性肠病

活动性溃疡性结肠炎粪菌移植严格供体选择:因无效而终止的随机对照试验的关键教训

Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-05-23

RESTORE-UC 试验为多中心、双盲、假手术对照随机试验,纳入 72 例中度至重度溃疡性结肠炎患者,随机接受 4 次厌氧制备的同种异体或自体供体粪菌移植。第 8 周无激素临床缓解在同种异体组 3 例与自体组 5 例之间无显著差异(P = .72),研究因无效而终止。

要点

  • 严格供体预选、厌氧处理和重复粪菌移植未提高第 8 周无激素临床缓解率。
  • 同种异体粪菌移植组 3 例 vs 自体粪菌移植组 5 例达到主要终点(P = .72)。
  • 基线总 Mayo 评分较低、细菌细胞计数较低和拟杆菌 2 型占比较高与主要应答相关。

核心结论

  • RESTORE-UC 试验未达到第 8 周无激素临床缓解增加的主要终点。
  • 作者认为进一步研究应额外考虑患者选择、灭菌假对照、给药前粪菌移植的频率、密度和活力。

研究设计与样本

  • RESTORE-UC 为多中心、双盲、假手术对照、随机试验(NCT03110289)。
  • 纳入中度至重度溃疡性结肠炎患者(总 Mayo 评分 4-10 分),随机接受 4 次厌氧制备的同种异体或自体供体粪菌移植。
  • 同种异体供体材料基于微生物细胞计数、肠型和特定菌属丰度进行严格筛选。
  • 主要终点为第 8 周无激素临床缓解(总 Mayo 评分 ≤2 分,无子评分 >1 分)。
  • 在达到计划纳入 108 例的 66%(n = 72)后进行了预先计划的无效分析。

主要发现

  • 共纳入 72 例患者,其中 66 例至少接受 1 次粪菌移植(同种异体粪菌移植组 n = 30,自体粪菌移植组 n = 36)。
  • 第 8 周分别有 3 例和 5 例患者达到主要终点无激素临床缓解(P = .72),表明同种异体粪菌移植未显示出至少 5% 的治疗差异优势。
  • 微生物组分析显示,同种异体粪菌移植后肠型转换数量在数值上多于自体粪菌移植,且当患者接受与基线自身肠型不同的肠型治疗时观察到更多转换(P = .01)。
  • 主要应答与基线较低的总 Mayo 评分、较低的细菌细胞计数和较高的拟杆菌 2 型 prevalence 相关。

局限性

  • 研究因无效而终止。
  • 作者认为进一步研究应额外考虑患者选择、灭菌假对照、给药前粪菌移植的频率、密度和活力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Rigorous donor preselection on microbiota level, strict anaerobic processing, and repeated fecal microbiota transplantation (FMT) administration were hypothesized to improve FMT induction of remission in ulcerative colitis (UC). METHODS: The RESTORE-UC trial was a multi-centric, double-blind, sham-controlled, randomized trial. Patients with moderate to severe UC (defined by total Mayo 4-10) were randomly allocated to receive 4 anaerobic-prepared allogenic or autologous donor FMTs. Allogenic donor material was selected after a rigorous screening based on microbial cell count, enterotype, and the abundance of specific genera. The primary endpoint was steroid-free clinical remission (total Mayo ≤2, no sub-score >1) at week 8. A pre-planned futility analysis was performed after 66% (n = 72) of intended inclusions (n = 108). Quantitative microbiome profiling (n = 44) was performed at weeks 0 and 8. RESULTS: In total, 72 patients were included, of which 66 received at least 1 FMT (allogenic FMT, n = 30 and autologous FMT, n = 36). At week 8, respectively, 3 and 5 patients reached the primary endpoint of steroid-free clinical remission (P = .72), indicating no treatment difference of at least 5% in favor of allogenic FMT. Hence, the study was stopped due to futility. Microbiome analysis showed numerically more enterotype transitions upon allogenic FMT compared with autologous FMT, and more transitions were observed when patients were treated with a different enterotype than their own at baseline (P = .01). Primary response was associated with lower total Mayo scores, lower bacterial cell counts, and higher Bacteroides 2 prevalence at baseline. CONCLUSION: The RESTORE-UC trial did not meet its primary endpoint of increased steroid-free clinical remission at week 8. Further research should additionally consider patient selection, sterilized sham-control, increased frequency, density, and viability of FMT prior to administration. CLINICALTRIALS: gov, Number: NCT03110289.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Caenepeel C, Deleu S, Vazquez Castellanos JF, et al. Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility. Clin Gastroenterol Hepatol. 2024. PMID: 38788915. doi:10.1016/j.cgh.2024.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。